Martingale Asset Management L P Xencor Inc Transaction History

Martingale Asset Management L P

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$24.77 - $29.9 $47,087 - $56,839	1,901 Added 3.49%	56,419 $1.41 Million
Q1 2023 May 12, 2023	BUY	$25.95 - $36.95 $23,329 - $33,218	899 Added 1.68%	54,518 $1.52 Million
Q4 2022 Feb 13, 2023	BUY	$24.79 - $30.86 $279,978 - $348,532	11,294 Added 26.68%	53,619 $1.4 Million
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $564,093 - $743,265	22,912 Added 118.02%	42,325 $1.1 Million
Q2 2022 Aug 11, 2022	SELL	$19.74 - $29.01 $57,226 - $84,099	-2,899 Reduced 12.99%	19,413 $531,000
Q4 2021 Feb 11, 2022	SELL	$33.67 - $43.44 $94,276 - $121,632	-2,800 Reduced 11.15%	22,312 $895,000
Q3 2021 Nov 12, 2021	BUY	$30.65 - $35.68 $278,792 - $324,545	9,096 Added 56.79%	25,112 $820,000
Q2 2021 Aug 13, 2021	SELL	$34.33 - $44.68 $75,423 - $98,161	-2,197 Reduced 12.06%	16,016 $552,000
Q1 2021 May 13, 2021	BUY	$40.81 - $53.88 $106,514 - $140,626	2,610 Added 16.73%	18,213 $784,000
Q4 2020 Feb 10, 2021	BUY	$36.63 - $47.63 $11,025 - $14,336	301 Added 1.97%	15,603 $680,000
Q3 2020 Nov 12, 2020	BUY	$30.09 - $43.02 $460,437 - $658,292	15,302 New	15,302 $593,000

216

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.